BioSpace News Archive

Curia, formerly AMRI, today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization headquartered in Camarillo, California.

BioSyent Inc. is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an agreement to license a unique technology application to support better treatment outcomes for patients with iron deficiencies in Canada and BioSyent’s international markets.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the enrollment has been completed for the Phase 1 clinical trial for Tacrolimus Inhalation Powder (“inhaled tacrolimus”).

Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that data from Qu’s RESTORE clinical trial was presented at the 16th Congress of the European Crohn’s and Colitis Organization (ECCO).

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today that it has received approval from the Spanish Drug Agency (AEMPS) for its Clinical Trial Application (CTA) to conduct a Phase IIb clinical trial with vafidemstat in patients with schizophrenia.

Nicox SA, an international ophthalmology company, announced that two internationally recognized experts in glaucoma, Robert N. Weinreb, M.D., Distinguished Professor and Chair, Ophthalmology and Director, Shiley Eye Institute, University of California San Diego, and Sanjay G. Asrani, M.D., Professor of Ophthalmology, Duke University, will be joining the Nicox Glaucoma Clinical Advisory Board.

Polymerase Chain Reaction is a tool used in medical and biological research labs to make millions of copies from small amount of DNA.

Erectile dysfunction is among the most commonly occurring sexual disorder. There are several reasons that may cause such disorder.

The increasing demand for custom-made nucleotides for the required sequence through analysis, forensic applications, drug production, and genetic testing has resulted from the decreasing cost of sequencing.

According to a recent report compiled by Transparency Market Research, the competitive landscape of the global medical device technologies market is estimated to show remarkable growth owing to the technological advancements in the health and medical sector.